P. J. Hughes
University of Birmingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by P. J. Hughes.
Biochemical Journal | 2001
P. J. Hughes; L E Twist; Jennifer Durham; M A Choudhry; Mark T. Drayson; R Chandraratna; Robert H. Michell; Christopher J. Kirk; G. Brown
HL60 promyeloid cells express both classes of oestrogen receptor (ERalpha and ERbeta). We show that hydrolysis of oestrone sulphate by steroid sulphatase is a major source of oestrone in HL60 cells, and that most of the released oestrone is not metabolized further to 17beta-oestradiol. Treatment of HL60 cells with retinoids or 1alpha,25-dihydroxyvitamin D3 increased steroid sulphatase mRNA and activity in parallel with the induction of CD11b, an early marker of myeloid differentiation that is expressed before the differentiating cells stop proliferating. Use of agonists and antagonists against retinoid receptor-alpha and retinoid receptor-X revealed that both classes of retinoid receptor can drive steroid sulphatase up-regulation. Steroid sulphatase activity fluctuates during the cell cycle, being highest around the transition from G1 to S phase. During the differentiation of HL60 cells induced by all-trans-retinoic acid or 1alpha,25-dihydroxyvitamin D3, there is increased conversion of 17beta-oestradiol into oestrone by an oxidative 17beta-hydroxysteroid dehydrogenase. Treatment of Caco-2 colon adenocarcinoma cells with all-trans-retinoic acid or 1alpha,25-dihydroxyvitamin D3 also increases 17beta-oestradiol oxidation to oestrone. An increase in local oestrone production therefore occurs in multiple cell types following treatment with retinoids and 1alpha,25-dihydroxyvitamin D3. The possible involvement of locally produced oestrogenic steroids in regulating the proliferation and differentiation of myeloid cells is discussed.
Cell Calcium | 1997
Stephen Tovey; Rita E. Godfrey; P. J. Hughes; Mokdad Mezna; Stephen D. Minchin; Katsuhiko Mikoshiba; Francesco Michelangeli
PCR analysis and immunoblotting with isoform specific antibodies was used to identify the presence of type I, II and III inositol 1,4,5-trisphosphate receptors (InsP3Rs) in rat testis. PCR analysis also revealed that rat testis express both forms of the S1 splice variant (S1+ and S1-), but only the S2- from of the S2 splice variant of the type I InsP3 receptor. PCR analysis was also used to identify InsP3R isoform expression at a cellular level using myoid, Sertoli and germ cells derived from the testis of Wistar rats. The extent of [3H]-InsP3 binding was found to be 9 times lower for testicular microsomes than for cerebellar microsomes, with a Bmax of 1.4 pmoles/mg protein compared to 12.5 pmoles/mg protein for cerebellar microsomes. The Kd for InsP3 binding to its receptor in testicular microsomes was 60 +/- 10 nM which was similar to that found for cerebellar microsomes (80 +/- 20 nM). InsP3-induced Ca2+ release (IICR) in testicular microsomes was found to have an EC50 (concentration which causes a half-maximal response) of 0.5 +/- 0.03 microM, also similar to that seen for cerebellar microsomes (0.3 microM). Maximal IICR occurred at about 20 microM InsP3, with up to 4% of total intracellular Ca2+ stores being mobilized as compared to between 10-30% for cerebellar microsomes. Time resolved IICR using stopped-flow spectrofluorimetry, showed the kinetics of IICR for this testis preparation to be monophasic with a maximum rate constant of 0.15 s-1 at 30 microM InsP3. The rate constants are 7 times slower than values for cerebellar microsomes under similar conditions (approximately 1 s-1) and taken together with the binding data support the proposal that the receptor density/Ca2+ store is approximately 8 times lower than seen in cerebellar microsomal vesicles. The pharmacological properties as assessed using heparin and InsP3 analogues also confirmed similar behaviour for testicular InsP3Rs and cerebellar InsP3Rs.
The Journal of Clinical Endocrinology and Metabolism | 2004
Robert M. Harris; D. M. Wood; L. Bottomley; S. Blagg; K. Owen; P. J. Hughes; Rosemary H. Waring; Christopher J. Kirk
Biochemical Society Transactions | 2001
Christopher J. Kirk; Robert M. Harris; D. M. Wood; Rosemary H. Waring; P. J. Hughes
Molecular and Cellular Biochemistry | 1995
Simon A. Rudge; P. J. Hughes; G. Brown; Robert H. Michell; Christopher J. Kirk
Biochemical Journal | 1994
Matthew N. Hodgkin; Andrew Craxton; Jocelyn B. Parry; P. J. Hughes; Barry V. L. Potter; Robert H. Michell; Christopher J. Kirk
Biochemical Society Transactions | 1996
Michelangeli F; Stephen Tovey; D.A. Lowes; R.F.I. Tien; Mokdad Mezna; H. McLELLAN; P. J. Hughes
Experimental Cell Research | 2003
Geoffrey Brown; P. J. Hughes; Robert H. Michell
Biochemical Society Transactions | 1997
Pat P. Ongusaha; P. J. Hughes; M. Hirata; John Davey; Robert H. Michell
Biochemical Society Transactions | 1993
Simon A. Rudge; P. J. Hughes; Christopher J. Kirk; Robert H. Michell